QIAGEN

In addition to promoting their brands, companies say their funding initiatives give them access to the expertise of top researchers and contribute to society.

There’s a new collaboration in the Parkinson’s disease development space, Cardiff Oncology kicks off a mid-phase study in colorectal cancer and Ocugen published a new review of COVAXIN.

The changes are unlikely to help people in developing countries but could reduce innovation among biopharma companies and ultimately do more harm than good.

The two companies will collaborate to market Verogen’s forensically validated NGS workflows alongside QIAGEN’s full range of forensic-grade chemistries and sample prep automation.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 6, 2020.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 9, 2020.

The increase reflects the positive financial impact COVID-19 has had on the European diagnostic company’s bottom line.

As the number of diagnosed cases of COVID-19 continue to increase across the globe and more and more governments are urging citizens to self-quarantine, the pharmaceutical and life sciences industry continues to work toward the development of a vaccine and therapies for the respiratory infection that was declared a pandemic by the World Health Organization last week. Here’s a biopharma industry overview as of late March 16.

Qiagen manufactures diagnostic tests for a variety of diseases including cancer and, currently, the coronavirus that causes COVID-19.